Physician profile
David E O Connor
NPI 1699798595
$2,076.26
in general payments reported to CMS, 2019-2025
15 companies · $234 in 2025
The $234 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $177 · 2020: $188 · 2021: $117 · 2023: $433 · 2024: $927 · 2025: $234.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,594.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,594.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $438.64 | 2020-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Corium, LLC | $242.71 | 2023-2025 | Azstarys |
| Teva Pharmaceuticals USA, INC. | $220.53 | 2023-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Supernus Pharmaceuticals, INC. | $202.62 | 2024-2025 | Qelbree |
| Abbvie INC. | $153.93 | 2023-2025 | |
| Alkermes, INC. | $128.68 | 2020-2021 | |
| Allergan, INC. | $127.43 | 2019 | |
| Janssen Pharmaceuticals, INC | $118.54 | 2019-2025 | Invega Sustenna, Invega Trinza |
| Neurocrine Biosciences, INC. | $116.64 | 2020-2024 | Ingrezza |
| Axsome Therapeutics, INC. | $109.72 | 2023-2024 | Auvelity |
| Indivior INC. | $56.03 | 2024 | Perseris |
| Ironshore Pharmaceuticals INC. | $48.41 | 2019-2024 | Jornay Pm |
| Noven Therapeutics, LLC | $46.35 | 2023-2024 | Secuado |
| Vertical Pharmaceuticals, LLC | $43.85 | 2019-2025 | Relexxii |
| Idorsia Pharmaceuticals US INC | $22.18 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David O Connor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.